Wakamoto Pharmaceutical Co., Ltd.

Hoechst Japan Limited

Mitsubishi Denki Kabushiki Kaisha

Hoechst Aktiengesellschaft

Masayoshi Goto

Shohei Sawaki

Yasuhiro Ootake

Yoshihiro Horio

Mitsuzi Agata

Sinji Inukai

Toshie Takahashi

Touru Oguma

Toshizo Tanaka

Takeo Ohmura

Kiyoshi Akiba

Nobutaka Demura

Masao Sakurai

Manami Umezawa

Jun Matsumoto

Hidekazu Suzuki

Ulrich Gebert

Hiroki Maruyama

Kenji Endo

Harald Furrer

Masanobu Takeuchi

Erhard Wolf

Hatsunori Toyofuku

Hiroe Suzuki

Hirokazu Suzuki

Mitsuji Agata

Yoshitami Ohashi

Miyako Fukushima

Takashi Sakaguchi

Tsutomu Osaki

Yoshinori Sakurai

Toshio Gohnai

Masakazu Ebie

Naomi Sasada

Keiko Naitou

In a battery accumulating apparatus, a charge current I from the charging solar battery is supplied to the storage battery through the switch , and charges the storage battery . The charge controller detects each cell voltage of the storage battery , and when any cell voltage reaches a prescribed value, the charge controller turns the switch which is in the ON status to the OFF status. The charge controller has a function which generates the charge currents I and I (I I ) whose levels are lower than the charge current I , according to the output from the charging solar battery , and which supplies the charge current I to the storage battery to charge the battery at the same time as the turning OFF of the switch . The storage battery is charged by the charge current I , and when any cell voltage reaches a prescribed value, the charge controller switches the charge current I to the charge current I , and supplies the charge current I to the storage battery

Battery accumulating apparatus

Aqueous drug composition having property of reversible thermosetting

An aqueous dispersion containing liposomes comprising yolk lecithin and/or soybean lecithin as lipids for forming liposomes wherein the dispersion contains a hydroxy acid and an amino acid, which hardly shows coloration, shows little leak of drugs encapsulated in the liposomes and is stable in a broad pH range.

Stable aqueous dispersions containing liposomes

A 1,2,4-oxadiazole derivative is represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a lower alkyl or cycloalkyl group, a lower alkyl group substituted with a halogen atom, a lower alkylamino group or a phenyl group; R.sup.2 represents a hydrogen atom, a lower dialkylamino group, a cyclic alkylamino group, a cyclic amino group having an oxygen or nitrogen atom in the ring, a phenyl group which may be substituted with a halogen atom, a pyridyl group, an imidazolyl group, an alkylimidazolyl group, a benzimidazolyl group or a 2-oxopyrrolidinyl group; and n is 1, 2 or 3. The derivative has excellent monoamine oxidase-inhibitory activity and is effective as a medicine for treating Parkinson's disease.

1,2,4-oxadiazole derivatives having monoamine oxidase B

A tetrazoleacetic acid derivative represented by the following general formula I: ##STR1## wherein in the formula I, R represents a hydrogen atom or a lower alkyl group; A is an alkylene group having 2 to 5 carbon atoms; Ar is selected from the group consisting of a phenyl group, a naphthyl group, a furyl group, a thienyl group, a benzofuryl group, and a benzothienyl group; wherein the Ar may be substituted with a lower alkyl group, a lower alkoxy group, a halogen atom, a lower haloalkyl group, an alkylthio group and an alkylsulfonylamino group shows excellent aldose reductase inhibitory activity, and is quite effective as an essential component of a preventive medicine and/or remedy for diabetic complications.

Tetrazoleacetic acid derivatives and method of aldose reductase

A tetrazoleacetic acid derivative represented by the following general formula (I): ##STR1## [in Formula (I), R.sub.1 represents a hydrogen atom or a lower alkyl group; R.sub.2, R.sub.3 and R.sub.4 are the same or different from each other and are selected from the group consisting of hydrogen, lower alkyl, halogen, lower haloalkyl, hydroxy and lower alkoxy; and tetrazol group is substituted at 1- or 2-position of naphthyl group] except for [5-(1-naphthyl)tetrazol-1-yl]acetic acid and ethyl ester thereof, or a salt thereof.

Tetrazoleacetic acid derivatives having aldose reductase inhibitory

A method of diagnosing renal diseases by detecting fragments of albumin in human urine. The detection of the fragments is carried out by, for example, immunological methods or liquid chromatography techniques.

Method of diagnosing renal diseases

Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula ##STR1## wherein R.sup.1 and R.sup.3 are the same or different and are each (C.sub.1 -C.sub.8)alkyl, ##STR2## R.sup.2 is (C.sub.1 -C.sub.4)alkyl; R.sup.4 and R.sup.5 are the same or different and are each hydrogen or (C.sub.1 -C.sub.2)alkyl; R.sup.6 is (C.sub.1 -C.sub.2)alkyl; and m, n and p are the same or different and are each 1, 2, 3, 4, 5 or 6; with the proviso that one of the groups R.sup.1 and R.sup.3 is ##STR3## or that R.sup.3 represents ##STR4## Some of the compounds of formula I are novel.

Therapeutic xanthine derivatives for the treatment of peptic ulcer

A tetrazoleacetic acid derivative represented by the following general formula (I): ##STR1## [in Formula (I), R.sub.1 represents a hydrogen atom or an alkyl group; R.sub.2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--] except for [5-(2-thienyl)tetrazol-1-yl] acetic acid, [5-(2-furyl)tetrazol-1-yl] acetic acid and ethyl esters thereof, or a salt thereof shows excellent aldose reductase inhibitory activity, has low toxicity to organisms and is quite effective as an essential component of a preventive medicine and/or remedy for diabetic complications.

Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory

The present invention relates to an aldose reductase inhibitor having the following formula: ##STR1## R.sub.1 is a hydrogen atom or --A--COOR.sub.5 (A is an alkylene group having 1 to 4 carbon atoms and R.sub.5 is a hydrogen atom or a lower alkyl group), and R.sub.2, R.sub.3 and R.sub.4 are the same as or different from each other and selected from the group consisting of a hydrogen atom, a hydroxy group, a halogen atom, a carboxyl group, an alkyl group, an amide group, an amino group, an alkoxy group, an aryl group, an aryloxy group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, a nitro group, --NHCOCOOR.sub.6 (R.sub.6 is a hydrogen atom or a lower alkyl group), a mono- or dialkylaminosulfonyl group, and a residual group having the following formula: ##STR2## (A and R.sub.5 are the same as in the above). The compounds defined in the above are excellent in aldose reductase inhibitory activity and low in toxicity. Therefore, those compounds are useful as a preventive agent and/or a remedy for diabetic complications such as neuropathy, retinopathy, nephropathy, cataracts and keratopathy.

Tetrazole derivatives and aldose reductase inhibition therewith

An anti-dementia agent comprising as an active ingredient an adenosine derivative is disclosed. The anti-dementia agent is useful in the therapy of various types of dementia, especially senile dementia. Examples of the adenosine derivative include L-N.sup.6 -phenylisopropyl-adenosine, 2-chloroadenosine, N.sup.6 -cyclohexyladenosine, adenosine-5'-(N-cyclopropyl)carboxamide.

Anti-dementia agents

Therapeutic agent for the treatment of peptic ulcer disease comprising as active ingredient at least one compound of formula I ##STR1## wherein R.sub.1 =5-oxohexyl,

Therapeutic agent for the treatment of peptic ulcer disease

A therapeutic agent for memory disturbance containing 1,2,3,6-tetrahydro-3-methyl-1-(5-oxohexyl)-7-propyl-purine-2,6-dione as its active ingredient and a method for treating a patient suffering from memory disturbance with such a therapeutic agent.

Therapeutic agent for memory disturbance

Growing community of inventors

Isehara, Japan

Masayoshi Goto